HER2 (2+) with gene amplification and HER2 (3+) (circumferential membrane staining that is complete and intense and in >10% of tumor cells) tumors are defined as HER2-positive tumors and are eligible for targeted anti-HER2 therapies [2]. The gene discussed is ERBB2; the disease is neoplasm.